While the increase in price target from $35 to $36 by Barclays indicates a slightly more positive outlook on Appian's valuation, the Underweight rating suggests that Barclays analysts still view the stock as potentially underperforming the broader market or its sector. This mixed signal could lead to neutral short-term price movement as investors digest both the positive and negative aspects of this analysis.